Overview

A Study of Treprostinil and a New Formulation of LY900014 in Healthy Japanese Participants

Status:
Completed
Trial end date:
2016-07-01
Target enrollment:
Participant gender:
Summary
The aims of this study are to evaluate: - The safety and tolerability of a single dose of treprostinil given subcutaneously (as an injection just under the skin) - The pharmacokinetic profile (how the body absorbs, breaks down, and gets rid of) of a single subcutaneous dose of a new LY900014 formulation in healthy Japanese participants. The study has two parts. Participants may only enroll in one part.
Phase:
Phase 1
Details
Lead Sponsor:
Eli Lilly and Company
Treatments:
Insulin
Insulin Lispro
Insulin, Globin Zinc
Treprostinil